ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announces board changes with the resignation of Mr. Yu Xiaoyong as a non-executive Director, effective September 30, 2024, and the nomination of Ms. Fu Dawei for the same role, pending shareholder approval at an upcoming EGM. Ms. Fu brings over 20 years of experience in investment and technology enterprise management to ImmuneOnco’s board.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.